Jennifer Tsialikas

Jennifer Tsialikas, PhD has extensive work experience in the biopharmaceutical industry. Jennifer currently holds the position of Principal Scientist Analytical Development at Century Therapeutics, Inc., starting in 2022. Prior to this, they worked at Adaptimmune, where they served as the Associate Director of Quality Control Analytical Science and Technology from 2018 to 2022. Jennifer also held positions as Manager, QC Analytical Science & Technology and Senior Scientist, Manufacturing Science & Technology at Adaptimmune. Jennifer's work at Adaptimmune involved leading cross-functional teams and focusing on the development and implementation of new analytical methods to support manufacturing.

Before joining Adaptimmune, Jennifer worked at WuXi Advanced Therapies as a Virologist in 2018, where they conducted testing for the presence of adventitious virus and replication competent viral vectors in gene therapy products. Jennifer utilized qRT-PCR and cell-based assays in a BSL2+ laboratory setting.

Jennifer's early career included a role as a Postdoctoral Fellow at the Children's Hospital of Philadelphia from 2016 to 2017. During their time as a postdoctoral fellow, they managed and executed a research project studying the unfolded protein response in mammalian cell culture and in the model organism, C. elegans. This work was funded by a NRSA T32 training grant and resulted in one first-author publication.

Jennifer Tsialikas earned an Associate of Science (A.S.) degree from Ocean County College in 2007. From 2007 to 2009, they attended Stockton University and obtained a Bachelor of Science (BS) degree in Biochemistry and Molecular Biology. Jennifer then went on to pursue a Doctor of Philosophy (Ph.D.) in Molecular Biology at Rowan University, completing their degree in 2016.